Intriguingly, Tc22 cells have been detected in populations of tumor-infiltrating lymphocytes (TILs) from ovarian cancer tissue that had been expanded, thereby comprising up to ~35% of the CD8 T cells in some patients, and the production of IL-22 by these CD8+ TILs correlated with increased recurrence-free survival. Here, CD8A is linked to ovarian carcinoma.